Ország: Dél-afrikai Köztársaság
Nyelv: angol
Forrás: South African Health Products Regulatory Authority (SAHPRA)
Knoll
IRUXOL® MONO OINTMENT SCHEDULING STATUS S1 PROPRIETARY NAME (and dosage form): IRUXOL ® MONO OINTMENT COMPOSITION Each 1 g of ointment contains: Collagenase Clostridiopeptidase A 1,20 units Proteases 0,24 units PHARMACOLOGICAL ACTION A 13.9 Special combinations. PHARMACOLOGICAL ACTION Iruxol ® mono ointment produces a gentle, bloodless and practically pain-free enzymatic debridement of wounds. Sloughs are dissolved or separated, thereby facilitating their removal. INDICATIONS For wound cleaning in various types of ulcerations and decubitus; in poorly healing wounds and necroses. CONTRA-INDICATIONS Additional preparations for topical use should not be applied, since such preparations may influence the activity of Iruxol ® mono ointment. DOSAGE AND DIRECTIONS FOR USE If not otherwise prescribed by the physician, Iruxol ® mono ointment is applied once daily in a layer of about 2 mm thickness. The ointment should be in close and even contact with the wound surface. In some cases it may be of advantage to apply the ointment twice daily. Completely dry and hard crusts should be softened by application of a moist dressing. Necrotic material which has separated should be removed when the dressing is changed. This can be done with gauze, forceps or bathing. As a matter of routine or for relief of irritation, it may be useful to cover the wound edge with zinc paste or a similar preparation. Iruxol ® mono ointment should be applied according to medical prescription. The end of treatment is determined by the physician. SIDE-EFFECTS AND SPECIAL PRECAUTIONS At the beginning of treatment a burning sensation and pain may be felt in the wound surface. This, however, results only in rare cases in discontinuance of treatment. Some patients may show signs of local irritation which Olvassa el a teljes dokumentumot